spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Dimebon 

 HSMN NewsFeed - 11 Apr 2011
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 7 Dec 2010
Medistem Announces New Management Team
Regenerative Medicine Personnel
 HSMN NewsFeed - 29 Mar 2010
Medivation Announces Reduction in Workforce
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Mar 2010
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Dec 2009
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jul 2009
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Mar 2009
Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Mar 2008
Medivation Announces Senior Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jan 2008
Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Jan 2008
Medivation Names Rohan Palekar Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Aug 2007
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jun 2007
Medivation's Dimebon(TM) Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Mar 2007
Medivation Announces Presentation of Full Top-Line Data From Dimebon(TM) Six-Month Trial at Major International Alzheimer's Disease Conference
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Jan 2007
Medivation Names Lisa Taylor Vice President of Commercial Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Sep 2006
Medivation Receives FDA Permission to Begin Dimebon Huntington's Disease Trial
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 21 Sep 2006
Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Sep 2006
Medivation Appoints Dr. Andrew A. Protter Vice President of Preclinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2006
Medivation Provides Update on Huntington's Disease IND
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 Mar 2006
Medivation Receives FDA Comments on Huntington's Disease IND
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 28 Feb 2006
Medivation Exceeds Patient Enrollment Target in Phase 2 Alzheimer's Disease Trial
Biopharmaceuticals Neurology
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
Dimebon
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.